CD155 reprograms glycolysis via the YAP/TEAD1-GLUT1 axis to promote lung adenocarcinoma progression and M2 macrophage polarization: a metabolic-immune target visualized by 18F-FDG PET/CT Authors: Zhiming Cheng, Shu Wang, Shuoyan Xu, Yuxiang Wang, Yao Diao, Bulin Du, Xuena Li, Yaming Li Published: 2025 ABSTRACT BackgroundCD155, an emerging immune checkpoint, contributes to tumor immune evasion and progression, but its roles in metabolic reprogramming and tumor-associated macrophages (TAMs) polarization in lung adenocarcinoma (LUAD) remain uncharacterized. This study combines molecular biology, metabolic imaging, and clinical data to elucidate CD155’s dual role in driving LUAD progression through glycolytic rewiring and immunosuppressive TAMs polarization.MethodsThrough immunohistochemistry (IHC) and 18F-FDG PET/CT imaging, we analyzed CD155 expression and its association with glycolysis in 80 LUAD patients. Functional assays and molecular studies revealed CD155-mediated regulation of tumor glycolysis and macrophage polarization via YAP/TEAD1-GLUT1 signaling. Xenograft models validated the in vivo findings, with 18F-FDG micro-PET imaging performing noninvasive metabolic profiling.ResultsCD155 was significantly overexpressed in LUAD tissues and positively correlated with advanced TNM stage, lymph node metastasis and elevated 18F-FDG uptake. Mechanistically, CD155 interacts with YAP, reducing YAP phosphorylation at Ser127 to promote its nuclear translocation and TEAD1 activation, thereby upregulating GLUT1 transcription. This signaling axis enhanced glycolysis, thereby fueling LUAD proliferation and migration. Notably, CD155-induced lactate production and extracellular acidification drove macrophage polarization toward the immunosuppressive M2 phenotype. In vivo, CD155 silencing suppressed tumor glucose metabolism and growth, whereas overexpression accelerated tumor progression, both dynamically monitored through 18F-FDG PET visualization.ConclusionsWe identify a novel CD155/YAP/TEAD1/GLUT1 axis that reprograms LUAD metabolism and facilitates immunosuppressive tumor microenvironment formation. CD155 functions as a metabolic-immune hub in LUAD, and its targeting could simultaneously suppress tumor growth and restore antitumor immunity, offering dual therapeutic advantages. Clinically, 18F-FDG PET/CT represents a noninvasive biomarker for CD155-driven metabolic aggression, potentially guiding precision immunotherapy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-025-07551-7. Introduction Lung cancer remains a leading threat to human health, with lung adenocarcinoma (LUAD) representing its most prevalent pathological subtype [1, 2]. Current standard therapies (surgery, radiotherapy, and chemotherapy) yield suboptimal outcomes for most LUAD patients, primarily due to late-stage diagnosis, metastatic progression, and interpatient heterogeneity [3, 4]. This underscores an urgent need for novel therapeutic strategies and actionable targets in LUAD management. Tumor immunotherapy has revolutionized cancer treatment by harnessing the immune system to eradicate malignant cells [5, 6]. Immunotherapy mainly includes immune checkpoint inhibitors, tumor vaccines, adoptive cell transfer and oncolytic virus therapy, among which immune checkpoint inhibitor therapy has been the subject of the most in-depth research [7–9]. Despite their status as a cornerstone in advanced lung cancer treatment, only 30% of patients respond to PD–L1 monotherapy, with immune escape constituting a critical barrier to efficacy [10]. Emerging evidence identifies metabolic reprogramming as a defining cancer hallmark: aerobic glycolysis (Warburg effect) generates lactate, acidifying the tumor microenvironment (TME), suppressing antitumor immunity and promoting metastasis. Notably, lactate-rich TMEs drive polarization of tumor-associated macrophages (TAMs) toward an immunosuppressive M2 phenotype, exacerbating immune escape. However, the molecular crosstalk between glycolysis and TAMs polarization in LUAD remains incompletely defined [11, 12]. CD155, a member of the Necl protein family, was initially recognized as a cell adhesion molecule regulating tumor proliferation, migration and adhesion [13, 14]. Recent studies reveal its role as an emerging immune checkpoint: CD155 inhibits CD8+ T cell function in the TME via TIGIT/CD96 signaling, thereby modulating tumor immunity and emerging as a potential target for checkpoint blockade [15–19]. Despite these insights, CD155’s functional significance in LUAD pathogenesis remains incompletely defined. Herein, we demonstrate that CD155 acts as a key metabolic-immune regulator in LUAD, orchestrating glycolysis and TAMs polarization via a previously unrecognized mechanism. Using 18F-FDG PET/CT, we demonstrate that CD155 expression correlates with tumor hypermetabolism. Mechanistically, CD155 activates the YAP/TEAD1 axis to upregulate GLUT1, accelerating glycolysis and lactate secretion. This metabolic reprogramming not only sustains tumor growth but also induces M2 polarization of TAMs, establishing an immunosuppressive TME. Our findings position CD155 at the intersection of tumor metabolism and immunity, proposing a novel therapeutic strategy that combines metabolic inhibition with immune checkpoint blockade to enhance LUAD treatment efficacy. Materials and methods Human tissue and immunohistochemistry (IHC) Eighty patients with pathologically confirmed LUAD were enrolled, and their clinical data were retrospectively collected. Inclusion criteria: (1) 18F-FDG PET/CT within 1 month preoperatively; (2) pathologically confirmed LUAD with adjacent normal lung tissue in surgical specimens. Exclusion criteria: (1) prior or concomitant other malignancies; (2) preoperative PET/CT imaging or treatment (chemotherapy, radiotherapy, targeted therapy). All participants provided written informed consent. This study was conducted in accordance with the Helsinki Declaration and approved by the Medical Science Research Ethics Committee of The First Affiliated Hospital of China Medical University (AF-SOP-07-1.1–01). Immunohistochemistry (IHC) was performed using the UltraSensitiveTM SP (Mouse/Rabbit) IHC kit (MXB Biotechnologies KT0305) following the manufacturer’s instructions. Paraffin sections were dewaxed in xylene, rehydrated through graded ethanol, and rinsed in water. Antigen retrieval was performed with EDTA. Sections were incubated overnight at 4 °C with primary antibodies: anti-PVR (1:100, ab267788, Abcam), anti-GLUT1 (1:200, ab115730, Abcam), anti-HK2 (1:200, ab209847, Abcam), anti-PKM2 (1:400, #4053, CST), anti-LDHA (1:300, #3582, CST), anti-CD163 (1:200, ab182422, Abcam), and anti-TGF-β (1:200, ab215715, Abcam). DAB (MXB Biotechnology Kit0016) was used for visualization. Immunostained sections were independently scored by two pathologists for staining intensity and positive tumor cell percentage using the Fromowitz criteria. The Fromowitz scoring system was adopted, with scoring conducted from two dimensions: “staining intensity” and “percentage of positive cells”. For staining intensity, the scores are defined as follows: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, tan), and 3 (strong staining, dark brown); for the percentage of positive cells, the scores are defined as: 0 (<5%), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (>75%). The final IHC score is calculated as “staining intensity score × percentage of positive cells score”, ranging from 0 to 12 points. 18F-FDG PET/CT imaging and data analysis After 6-hour fasting (blood glucose < 11 mmol/L), patients received intravenous 18F-FDG (3.7 MBq/kg). After 1-hour rest, imaging was performed using a Biograph mCT PET/CT scanner (Siemens, Germany). Images were analyzed on a Syngo workstation (True D software) with a 50% threshold. Regions of interest (ROIs) were auto-delineated to extract SUVmax, SUVmean, metabolic tumor volume (MTV), and total lesion glycolysis (TLG = SUVmean × MTV). Cell lines and culture Human bronchial epithelial cells (HBE), LUAD cell lines (A549, H1299, H1975, PC9, Calu-3, H1650, H1395, HCC827), HEK-293 T cells and THP-1 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Culture media: A549 in DMEM/F12 (Gibco 11330032); Calu-3 and HEK-293 T in DMEM (Gibco 11965092); H1299, H1975, PC9, H1650, H1395, HCC827, THP-1, and HBE in RPMI-1640 (Gibco 11875093), each supplemented with 10% fetal bovine serum (FBS, Gibco 10099141). Cells were maintained at 37 °C with 5% CO2. Transient cell transfection For CD155 knockdown: H1299 cells (50–60% confluent) were transfected with CD155 siRNA or negative control (si–NC; RiboBio, Guangzhou) using Lipofectamine® 3000 (Invitrogen L3000015). Cells were harvested 72 hours post-transfection. For TEAD1 knockdown: A549 cells (70% confluent) were transfected with TEAD1 siRNA or si–NC (RiboBio) using Lipofectamine® 3000. Cells were harvested 48 hours post-transfection. siRNA sequences are listed in Supplemental Table S1. Lentivirus infection To establish CD155-overexpressing stable A549 cells, lentiviral infection (Shanghai Genechem) was performed. Briefly, 4 × 10⁴ cells/well were seeded in 6-well plates with HitransG A solution and cultured overnight to 20–30% confluence. Cells were infected with HitransG P solution at multiplicity of infection (MOI) 20; medium was replaced with fresh complete medium after 16 hours. Stable cells were selected with 2 μg/ml puromycin (Biosharp BL528A) 72 hours later, and CD155 expression was verified by qRT-PCR and Western blot. Plasmid sequences are in Supplemental Table S2. RNA isolation and quantitative reverse transcriptase-polymerase chain reaction (qRT‒PCR) Total RNA was extracted with TRIZOL (TaKaRa 9108), reverse-transcribed to cDNA using PrimeScript™ RT reagent Kit (TaKaRa ‌RR037A‌), and quantified with TB Green Premix Ex Taq II kit (TaKaRa RR820A) on a LightCycler 480 System II (Roche). β-actin served as the internal control, and relative expression was calculated by the 2-ΔΔCt method. Primer sequences are in Supplemental Table S3. Protein extraction and Western blot Cells were lysed in RIPA buffer (Beyotime Biotechnology P0013 K) with phenylmethylsulfonyl fluoride (PMSF, Beyotime Biotechnology ST505) and phosphatase inhibitor (Beyotime Biotechnology P1082), sonicated, and centrifuged (12,000 rpm, 30 min, 4 °C); supernatants were collected for bicinchoninic acid (BCA) protein quantification (Beyotime Biotechnology P0010). Nuclear and cytoplasmic proteins were extracted using a commercial kit (Beyotime Biotechnology P0028). Proteins were separated by polyacrylamide gel electrophoresis (PAGE, Epizyme rapid gel kit), transferred to polyvinylidene fluoride (PVDF) membranes (Millipore), and blocked with rapid sealing solution (Beyotime Biotechnology P0252) at room temperature. Membranes were incubated overnight at 4 °C with primary antibodies: anti-PVR (1:1000, ab267788, Abcam), anti-GLUT1 (1:10000, ab115730, Abcam), anti-HK2 (1:1000, ab209847, Abcam), anti-PKM2 (1:1000, #4053, CST), anti-LDHA (1:1000, #3582, CST), anti-YAP (1:1000, #14074, CST), anti-phospho-YAP (1:1000, Ser127, #13008, CST), anti-TEAD1 (1:1000, ab133533, Abcam), anti-β-actin (1:5000, AF7018, Affinity), anti-Histone-H3 (1:1000, AF0863, Affinity), anti-Bcl-2 (1:1000, AF6139, Affinity), anti-Bax (1:1000, AF0120, Affinity). Membranes were then incubated with secondary antibodies at room temperature for 1 hour. Protein bands were detected by enhanced chemiluminescence (ECL, Beyotime Biotechnology P0018), normalized to β-actin, and quantified via ImageJ. Cell metabolic assays To investigate the effects of CD155 on glucose metabolism in LUAD cells, we detected the uptake of 18F-FDG, lactate production, ATP production and the extracellular pH. After regulating the expression of CD155 in LUAD cells, we first detected the uptake of 18F-FDG using a γ-counter (CAPINTEC). 18F-FDG is a glucose analog, and the uptake of glucose by cells can be reflected by the detection of 18F-FDG activity. The cell culture medium supernatant was collected, and the pH was measured with a pH meter (Mettler Toledo) within 2 minutes. The lactate content was determined with the lactate assays kit (Nanjing Jiancheng A019-2-1). The ATP content was determined with an ATP kit (Nanjing Jiancheng A095-1-1). Cell viability CCK-8 assays Cell viability was assessed by CCK-8 assays. After CD155 modulation, cells were seeded in 96-well plates (3000 cells/100 μl/well, ≥ 3 replicates) and cultured at 37 °C with 5% CO₂. CCK-8 reagent (Beyotime Biotechnology C0038) was added at 24, 48, and 72 hours; absorbance was measured after 1-hour incubation using a microplate reader (Thermo Fisher Scientific). Experiments were repeated ≥ 3 times. Colony formation assays CD155-modulated LUAD cells (500 cells/well) were seeded in 6-well plates and cultured at 37 °C with 5% CO₂ for 14 days. Colonies were fixed with 4% paraformaldehyde (Beyotime Biotechnology P0099), stained with crystal violet (Solarbio G1063), photographed, and counted using ImageJ. Flow cytometry Apoptosis was detected using an apoptosis kit (BD 556547). Cells were washed with precooled PBS, resuspended (1 × 10⁵ cells/100 μl) in binding buffer, stained with 5 μl Annexin V-FITC and 5 μl PI for 15 minutes at room temperature (with negative and single-stain controls), and analyzed by flow cytometry (BD). Wound healing assays CD155-modulated LUAD cells in 6-well plates (95–100% confluent) were scratched vertically with a 200 µL pipette tip, washed with PBS, and cultured in serum-free medium. Images were captured at 0 and 24 hours under a light microscope. Transwell assays Transwell chambers (Corning 3422) were placed in 24-well plates with 600 μl 10% FBS-containing medium in the lower chamber. CD155-modulated cells (2 × 10⁵) in serum-free medium were added to the upper chamber, cultured at 37 °C with 5% CO₂ for 24 hours, fixed with 4% paraformaldehyde, stained with crystal violet, washed, and photographed. THP-1 induction and Co-culture THP-1 cells were seeded in 12-well plates and differentiated into macrophages with 100 ng/ml phorbol 12-myristate 13-acetate (PMA, Solarbio IP1010) for 48 hours. CD155-modulated LUAD cells and their supernatants were collected. Transwell chambers were placed in 12-well plates: macrophages in the lower chamber and LUAD cells in the upper chamber were co-cultured at 37 °C with 5% CO₂ for 48 hours. THP-1-derived macrophages were harvested for subsequent experiments. Immunofluorescence CD155-modulated LUAD cells were washed with PBS, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 (Solarbio T8200), and blocked with 10% goat serum (Solarbio SL038)/1% BSA (Beyotime Biotechnology ST023)/0.3 M glycine (Beyotime Biotechnology ST085) for 1 hour at room temperature. Primary antibodies were incubated overnight at 4 °C; after PBS washes, fluorescent secondary antibodies were added and incubated in the dark at room temperature. DAPI (Solarbio C0065) was used for nuclear staining, and images were captured using a fluorescence microscope. Antibodies used: anti-YAP (1:100, #14074, CST), anti-CD68 (1:50, ab955, Abcam), anti-CD163 (1:200, ab87099, Abcam), goat anti-rabbit IgG H&L (Alexa Fluor® 488, 1:1000, ab150077, Abcam), goat anti-mouse IgG H&L (Alexa Fluor® 647, 1:1000, ab150115, Abcam). Enzyme-linked immunosorbent assays (ELISA) The supernatant from co-cultured macrophages was centrifuged (40000 rpm, 20 minutes) and used for ELISA (Ruixin Biotech). Standard, blank, and sample wells were set up; standards, diluent, or samples were added, followed by horseradish peroxidase (HRP)-labeled detection antibodies, and incubated at 37 °C in the dark. For TGF-β detection, samples were preactivated with HCl and neutralized with NaOH. Plates were washed, substrate was added, incubated in the dark at 37 °C, stopped, and absorbance was measured. Cytokine concentrations were calculated using standard curves. Molecular Docking Molecular docking prediction was performed using the HDOCK online platform (http://hdock.phys.hust.edu.cn/). The protein structures of CD155 (UniProt ID: P15151) and YAP (UniProt ID: P46937) were obtained from the UniProt database (https://www.uniprot.org/) for docking analysis. A fast Fourier transform algorithm was used to model the binding of the two proteins, and the sampled binding modes were evaluated using the Docking Score, with consideration of hydrogen bonds and van der Waals forces. The three-dimensional conformation and interactions of the protein-protein docking complex were visualized using PyMOL software. Coimmunoprecipitation (Co–IP) assays To detect CD155-YAP interaction, Co–IP (Absin abs955) was performed. Cells were lysed in pre-cooled lysis buffer with PMSF, sonicated, and centrifuged (14,000 × g, 10 minutes, 4 °C). Supernatants were incubated with Protein A/G for 1 hour at 4 °C, centrifuged, and incubated with 2 μg primary antibodies (anti-PVR: 1:30, ab205304, Abcam; anti-YAP: 1:50, #14074, CST; rabbit IgG isotype control: ab172730, Abcam) at 4 °C. Immunoprecipitates were analyzed by Western blot. Dual-luciferase reporter assays JASPAR predicted TEAD1 binding sites in the GLUT1 promoter (Supplemental Table S5). The GLUT1 promoter (wild-type and mutant) was cloned into a luciferase reporter vector, co-transfected with TEAD1 overexpression plasmid or empty vector (SyngenTech) into HEK293-T cells. Firefly and Renilla luciferase activities were measured using the Dual-Lumi™ II kit (Beyotime Biotechnology RG088S) with a microplate reader (Thermo Fisher). Sequences are in Supplemental Table S5. Chromatin immunoprecipitation (ChIP) assays ChIP assays (Absin abs50034) validated TEAD1-GLUT1 promoter interaction, using anti-TEAD1 antibody (1:50, GTX32918, GeneTex) and GLUT1 promoter-specific ChIP primers (Servicebio). Bound DNA was PCR-amplified and visualized on 1.5% agarose gels. Primer sequences are in Supplemental Table S6. Xenograft models and micro-PET scans Four-week-old female BALB/c nude mice (20–25 g; Beijing Huafukang) were housed in specific pathogen-free (SPF) conditions. The study was approved by China Medical University Institutional Animal Care and Use Committee (IACUC, KT2022352). Twenty mice of similar size were randomly divided into the H1299 group and the A549 group, with 10 mice in each group. Subcutaneous xenograft models were established by injecting LUAD cells into the right leg. Tumor volume (V=a × b²/2) was measured every 3 days. When the H1299 tumors reached 5 × 5 mm, the mice were randomly divided into two groups of 5 animals each. Intratumoral injections were performed using 5 nmol of si-CD155 or si–NC (purchased from RiboBio) dissolved in 100 µL of RNase-free water. For the A549 stable cell line (constructed via lentivirus), subcutaneous xenograft models were established and randomly assigned to a control group and an overexpression group, with 5 mice in each group. Tumor measurements were conducted over a period of 2 weeks. The maximum size allowed for the tumors to grow in the mice was 2000 mm3. For micro-PET (Madic) analysis: Mice fasted for 6 hours received tail vein injection of 18F-FDG (370 kBq/g), rested for 30 minutes, and imaged under 2% isoflurane anesthesia (15 minutes/bed, 2 beds total). Images were reconstructed with 3D-OSEM (physical resolution: 1.3 mm; image resolution: 0.9105 × 0.9 × 0.9 mm; sensitivity: 6%; noise equivalent count: 226 kcps). PET images were processed with Metis viewer software; ROIs were delineated, and SUVmax was calculated. After imaging, tumors were isolated, weighed, paraffin-embedded, and subjected to hematoxylin and eosin (H&E) and IHC staining. Statistical analysis All experiments were repeated ≥ 3 times. Normally distributed data are presented as mean ± SEM, with differences between two groups analyzed by Student’s t-test and among multiple groups by one-way ANOVA. Non-normally distributed data are presented as median (quartiles), with differences between two groups analyzed by Mann-Whitney U test. Categorical data were compared by chi-square test; correlations by Spearman’s analysis. SPSS 27.0 and GraphPad Prism 7.0 were used; p < 0.05 was considered significant. A post-hoc power analysis was performed using G*Power 3.1 software to verify the adequacy of the collected sample size. Results CD155 is highly expressed in LUAD and is related to glycolysis First, bioinformatics analysis identified that high CD155 expression in lung adenocarcinoma (LUAD) correlates significantly with poor overall survival (OS) and first progression survival (FP) (Fig. 1A and B). Herein, we first confirmed CD155 protein expression in LUAD tissues via immunohistochemistry (IHC), which localized predominantly to tumor cell membranes—consistent with prior observations. IHC staining further demonstrated that CD155 was predominantly positive in primary LUAD tissues but expressed at low or negligible levels in paracancerous tissues (≥3 cm from the tumor; Fig. 1C and D), with significantly higher relative expression in primary versus paracancerous tissues. Additionally, CD155 expression was abnormally upregulated in 8 human lung cancer cell lines compared to normal human bronchial epithelial (HBE) cells (Fig. 1E and F), with the highest levels in H1299 cells and the lowest in A549 cells—aligning with previous reports [20].Fig. 1Upregulated CD155 expression in LUAD tissues and CD155 was positively correlated with glycolysis. A–B Bioinformatics analysis of the impact of CD155 expression level on prognosis in LUAD. C Immunohistochemical analysis of CD155 protein in LUAD tissues (×400). D Quantifed data of immunohistochemistry. The expression level of CD155 in lung adenocarcinoma tissues was 4.46 ± 0.29, while that in adjacent normal lung tissues was 1.67 ± 0.16. E qRT-PCR was used to detect the mRNA expression level of CD155 in various lung cancer cell lines (n = 3). F Western blot was employed to determine the protein expression level of CD155 in various lung cancer cell lines (n = 3). G Representative CD155 expression and 18F-FDG PET/CT images (×400). H Correlation of CD155 expression with 18F-FDG uptake and PET/CT metabolic parameters SUVmax, SUVmean, MTV and TLG. I ROC curve for predicting CD155 expression by SUVmax. J Bioinformatics analysis of the correlation between CD155 and glycolysis-related proteins in LUAD. K–L Correlation between CD155 expression and glycolytic related proteins GLUT1, HK2, PKM2 and LDHA (×400). *p < 0.05, ***p < 0.001 Upregulated CD155 expression in LUAD tissues and CD155 was positively correlated with glycolysis. A–B Bioinformatics analysis of the impact of CD155 expression level on prognosis in LUAD. C Immunohistochemical analysis of CD155 protein in LUAD tissues (×400). D Quantifed data of immunohistochemistry. The expression level of CD155 in lung adenocarcinoma tissues was 4.46 ± 0.29, while that in adjacent normal lung tissues was 1.67 ± 0.16. E qRT-PCR was used to detect the mRNA expression level of CD155 in various lung cancer cell lines (n = 3). F Western blot was employed to determine the protein expression level of CD155 in various lung cancer cell lines (n = 3). G Representative CD155 expression and 18F-FDG PET/CT images (×400). H Correlation of CD155 expression with 18F-FDG uptake and PET/CT metabolic parameters SUVmax, SUVmean, MTV and TLG. I ROC curve for predicting CD155 expression by SUVmax. J Bioinformatics analysis of the correlation between CD155 and glycolysis-related proteins in LUAD. K–L Correlation between CD155 expression and glycolytic related proteins GLUT1, HK2, PKM2 and LDHA (×400). *p < 0.05, ***p < 0.001 Clinical correlation analysis of LUAD patient data (age, sex, smoking status, lymph node metastasis and clinical stage) revealed that CD155 expression (based on IHC scores) strongly associated with smoking status, lymph node metastasis and clinical stage but not with age or sex (Table 1). These findings confirm aberrant CD155 overexpression in LUAD, highlighting its potential as a prognostic biomarker and therapeutic target.Table 1Association of CD155 expression with clinicopathological parameters from LUAD patientsClinical characteristicsNCD155 expressionlevel (mean ± standarddeviation)tPAge (year)0.720.477≤60414.66 ± 2.67>60394.25 ± 2.55Gender1.420.165Male454.82 ± 2.69Female354.00 ± 2.44Smoking status4.27<0.001 ***Former or current345.77 ± 2.47Never463.49 ± 2.27Lymphatic metastasis−2.690.009 **Negative393.69 ± 2.54Positive415.20 ± 2.48Clinical stage−2.620.010 *I, II433.78 ± 2.47III, IV375.25 ± 2.56*P < 0.05, **P < 0.01, ***P < 0.001 Table 1Association of CD155 expression with clinicopathological parameters from LUAD patientsClinical characteristicsNCD155 expressionlevel (mean ± standarddeviation)tPAge (year)0.720.477≤60414.66 ± 2.67>60394.25 ± 2.55Gender1.420.165Male454.82 ± 2.69Female354.00 ± 2.44Smoking status4.27<0.001 ***Former or current345.77 ± 2.47Never463.49 ± 2.27Lymphatic metastasis−2.690.009 **Negative393.69 ± 2.54Positive415.20 ± 2.48Clinical stage−2.620.010 *I, II433.78 ± 2.47III, IV375.25 ± 2.56*P < 0.05, **P < 0.01, ***P < 0.001 Association of CD155 expression with clinicopathological parameters from LUAD patients *P < 0.05, **P < 0.01, ***P < 0.001 18F-FDG is a glucose analog, which can display the glucose metabolism level of tissues, organs and lesions in vivo through PET/CT [21]. We explored the relationship between CD155 expression and glucose metabolism in LUAD. 18F-FDG uptake was significantly elevated in LUAD lesions with high CD155 expression, compared to weak uptake in low-expression lesions (Fig. 1G). Semi-quantitative analysis further revealed positive correlations between CD155 expression and key metabolic parameters: SUVmax (r = 0.439, P < 0.001), SUVmean (r = 0.435, P < 0.001), MTV (r = 0.272, P < 0.05), and TLG (r = 0.421, p < 0.001) (Fig. 1H), implicating CD155 in regulating LUAD glucose metabolism. We calculated the cutoff value of SUVmax for predicting CD155 expression via the ROC curve (Fig. 1I), which was 6.34. The corresponding sensitivity was 0.76, specificity was 0.567, and AUC was 0.699. With a p-value of 0.003, the result was statistically significant. Based on the experimental results, using the correlation between CD155 expression and SUVmax as the indicator, G*Power 3.1 software was used for calculation under the parameters of α = 0.05 (two-tailed) and sample size n = 80. The resulting power was 0.97, which verifies that the 80 cases meets the requirement of statistical power To mechanistically link CD155 to glycolysis, TCGA dataset analysis showed positive correlations between CD155 and glycolysis-related proteins (GLUT1, HK2, PKM2, LDHA) in LUAD (Fig. 1J). IHC staining confirmed that these glycolytic proteins were predominantly overexpressed in primary LUAD tissues with high CD155 (Fig. 1K), and Spearman correlation analysis validated significant positive associations between CD155 IHC scores and those of GLUT1 (r = 0.460, p < 0.001), HK2 (r = 0.445, P < 0.001), PKM2 (r = 0.255, p < 0.05) and LDHA (r = 0.433, P < 0.001) (Fig. 1L). Collectively, these results establish a novel link between CD155 overexpression and enhanced glycolysis in LUAD, expanding its potential role in tumor metabolism. CD155 promotes glycolysis, proliferation and migration of LUAD cells and inhibits apoptosis We established cellular models by knocking down CD155 in H1299 cells using CD155-specific siRNA (si-CD155) or a negative control siRNA (si–NC), and by stably overexpressing CD155 in A549 cells using a CD155-encoding lentivirus (lv-CD155) versus an empty vector. qRT-PCR and Western blot confirmed successful CD155 modulation (Fig. 2A and B).Fig. 2CD155 regulates the glycolysis and tumor progression of LUAD in vitro. A–B Expression of C155 after transfection by qRT‒PCR and Western blot analysis. C–E Cellular 18F-FDG uptake, lactate levels in the culture medium and ATP production were significantly decreased in the downregulation of CD155 group (si-CD155) and increased in the upregulation of CD155 group (lv-CD155). F The pH of the culture medium was significantly increased in the downregulation of CD155 group (si-CD155) and decreased in the upregulation of CD155 group (lv-CD155). G Relative expression levels of glycolysis-associated proteins detected by Western blot. H–I CCK-8 and colony formation assays were used to detect cell proliferation. Cell proliferation decreased in the downregulation of CD155 group (si-CD155) and increased in the upregulation of CD155 group (lv-CD155). J–K Wound-healing and Transwell assays (×200) were used to detect cell migration. Cell migration decreased in the downregulation of CD155 group (si-CD155) and increased in the upregulation of CD155 group (lv-CD155). L Flow cytometry and Western blot were used to detect cell apoptosis. Cell apoptosis increased in the downregulation of CD155 group (si-CD155) and decreased in the upregulation of CD155 group (lv-CD155). An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 CD155 regulates the glycolysis and tumor progression of LUAD in vitro. A–B Expression of C155 after transfection by qRT‒PCR and Western blot analysis. C–E Cellular 18F-FDG uptake, lactate levels in the culture medium and ATP production were significantly decreased in the downregulation of CD155 group (si-CD155) and increased in the upregulation of CD155 group (lv-CD155). F The pH of the culture medium was significantly increased in the downregulation of CD155 group (si-CD155) and decreased in the upregulation of CD155 group (lv-CD155). G Relative expression levels of glycolysis-associated proteins detected by Western blot. H–I CCK-8 and colony formation assays were used to detect cell proliferation. Cell proliferation decreased in the downregulation of CD155 group (si-CD155) and increased in the upregulation of CD155 group (lv-CD155). J–K Wound-healing and Transwell assays (×200) were used to detect cell migration. Cell migration decreased in the downregulation of CD155 group (si-CD155) and increased in the upregulation of CD155 group (lv-CD155). L Flow cytometry and Western blot were used to detect cell apoptosis. Cell apoptosis increased in the downregulation of CD155 group (si-CD155) and decreased in the upregulation of CD155 group (lv-CD155). An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 Given our earlier correlation between CD155 and glucose metabolism, we first assessed glycolytic activity [22, 23]. 18F-FDG uptake was reduced in CD155-knockdown H1299 cells but increased in CD155-overexpressing A549 cells compared to controls (Fig. 2C). Consistently, CD155 knockdown inhibited lactate production in H1299 cells, while overexpression promoted lactate secretion in A549 cells (Fig. 2D), a key glycolytic end product. ATP production, a critical energy output of glycolysis, was similarly suppressed by CD155 knockdown in H1299 and enhanced by overexpression in A549 (Fig. 2E). Reflecting altered lactate release, the medium pH rose in CD155-knockdown H1299 cultures (reduced acidification) and fell in CD155-overexpressing A549 cultures (increased acidification) versus controls (Fig. 2F). These data collectively demonstrate that CD155 promotes glycolytic flux in LUAD cells. We next explored underlying mechanisms by evaluating glycolysis-associated proteins. Western blot showed that CD155 knockdown in H1299 cells reduced GLUT1, HK2, PKM2, and LDHA expression, whereas CD155 overexpression in A549 cells upregulated these proteins (Fig. 2G), indicating CD155 regulates glycolysis via these key mediators. To link CD155-driven glycolysis to tumorigenesis, we assessed cellular behaviors. CCK-8 and colony formation assays revealed that CD155 knockdown inhibited H1299 cell proliferation, while overexpression enhanced A549 proliferation (Fig. 2H and I). Wound-healing and Transwell assays demonstrated that CD155 knockdown impaired H1299 migration, whereas overexpression boosted A549 migration (Fig. 2J and K). The percentage of apoptotic cells was detected by flow cytometry, and the expression levels of the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax were detected by Western blot. These two methods were used together to reflect the level of cell apoptosis. Flow cytometry and Western blot further showed that CD155 knockdown promoted H1299 apoptosis, while overexpression suppressed A549 apoptosis (Fig. 2L). Together, these functional assays establish that CD155 promotes LUAD glycolysis (via upregulating key glycolytic proteins and enhancing glycolytic outputs) and drives malignant phenotypes (proliferation, migration, and anti-apoptosis), highlighting its potential as a mechanistic node in LUAD progression. CD155 promotes the progression of LUAD by regulating glycolysis To determine whether CD155 modulates LUAD cellular behaviors through glycolysis, we treated CD155-overexpressing A549 cells with the glycolysis inhibitor 2-deoxy-D-glucose (2-DG, MCE HY-13966) and assessed functional outcomes [24]. Lactate production assays confirmed that 2-DG abrogated the CD155-induced increase in lactate secretion (Fig. 3A), validating glycolysis as a downstream target of CD155.Fig. 3CD155 regulates LUAD proliferation, migration and apoptosis through glycolysis. A Lactate levels in the culture medium validated the glycolysis inhibitor 2-DG blocking the glycolysis process. B–C CCK-8 and colony formation assays were used to detect cell proliferation. D Transwell assays (×200) was used to detect cell migration. E Flow cytometry was used to detect cell apoptosis. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 CD155 regulates LUAD proliferation, migration and apoptosis through glycolysis. A Lactate levels in the culture medium validated the glycolysis inhibitor 2-DG blocking the glycolysis process. B–C CCK-8 and colony formation assays were used to detect cell proliferation. D Transwell assays (×200) was used to detect cell migration. E Flow cytometry was used to detect cell apoptosis. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 Functionally, CCK-8 and colony formation assays revealed that co-treatment with 2-DG significantly reduced the enhanced proliferation of CD155-overexpressing A549 cells compared to CD155 overexpression alone (Fig. 3B and C). Similarly, Transwell assays demonstrated that 2-DG reversed the CD155-mediated promotion of cell migration (Fig. 3D). Conversely, apoptosis levels were higher in the CD155-overexpressing with 2-DG group than in the CD155-overexpressing group (Fig. 3E), indicating 2-DG counteracted the anti-apoptotic effect of CD155. These findings establish a causal link: CD155 drives LUAD progression by enhancing glycolysis, which in turn enables tumor cells to rapidly generate energy, accelerate proliferation, and augment migratory capacity. This mechanistic insight not only clarifies how CD155 promotes malignant phenotypes but also supports the potential of combining CD155 targeting with glycolysis inhibition as a therapeutic strategy for LUAD. CD155 binds to YAP and promotes TEAD1-mediated transcription of GLUT1 The Hippo pathway is known to regulate tumor proliferation, apoptosis, invasion, and migration, and its key transcription factor TEAD1 directly modulating GLUT1 transcription [25–27]. As a transcription factor, TEAD1 primarily functions in the nucleus, and its activity is governed by the upstream coactivator YAP [28]. Notably, CD155 has been implicated in protein phosphorylation [29], prompting us to explore its potential crosstalk with the Hippo-YAP/TEAD1 axis. To investigate CD155-YAP interactions, molecular docking via HDOCK predicted stable binding between CD155 and YAP, mediated by a hydrogen bond between CD155 Ser-44 and YAP Ile-54 (docking score: − 266.85; confidence score: 0.9119; Fig. 4A). Reciprocal co-immunoprecipitation (Co–IP) in H1299 cells confirmed this physical interaction (Fig. 4B), validating their direct association.Fig. 4CD155 regulates the YAP/TEAD1 signaling pathway of LUAD. A Molecular docking shows that there is a hydrogen bond interaction between CD155 and YAP. B Co–IP experiment verified the combination of CD155 and YAP. C Western blot analysis of CD155 affected the expression of YAP and p-YAP proteins. D A nuclear/cytoplasmic protein extraction assays revealed that CD155 changes the phosphorylation level of YAP in the cytoplasm and affects the distribution of YAP in the nucleus. E Immunofluorescence assays indicated that CD155 drove the nuclear translocation of YAP in LUAD cells (×400). F Dual-luciferase reporter assays were used to determine the transcriptional regulation of GLUT1 by TEAD1. G ChIP assays were used to verify the binding of TEAD1 to GLUT1 promoter and the binding sequence was TACTTTCCAT. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). **P < 0.01, ***P < 0.001; ns, no significance CD155 regulates the YAP/TEAD1 signaling pathway of LUAD. A Molecular docking shows that there is a hydrogen bond interaction between CD155 and YAP. B Co–IP experiment verified the combination of CD155 and YAP. C Western blot analysis of CD155 affected the expression of YAP and p-YAP proteins. D A nuclear/cytoplasmic protein extraction assays revealed that CD155 changes the phosphorylation level of YAP in the cytoplasm and affects the distribution of YAP in the nucleus. E Immunofluorescence assays indicated that CD155 drove the nuclear translocation of YAP in LUAD cells (×400). F Dual-luciferase reporter assays were used to determine the transcriptional regulation of GLUT1 by TEAD1. G ChIP assays were used to verify the binding of TEAD1 to GLUT1 promoter and the binding sequence was TACTTTCCAT. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). **P < 0.01, ***P < 0.001; ns, no significance YAP activity is tightly regulated by phosphorylation (Ser127), which affects its stability, subcellular localization, and ability to enhance TEAD1-mediated transcription. Western blot analysis revealed that CD155 knockdown in H1299 cells increased phosphorylated YAP (p-YAP Ser127) and decreased total YAP, whereas CD155 overexpression in A549 cells reduced p-YAP (Ser127) and elevated total YAP (Fig. 4C). These findings indicate that CD155 inhibits YAP phosphorylation (Ser127) to stabilize YAP protein. Subcellular fractionation and immunofluorescence staining further demonstrated that CD155 modulates YAP nuclear translocation. CD155 knockdown in H1299 cells reduced nuclear YAP levels, while CD155 overexpression in A549 cells increased nuclear YAP (Fig. 4D). Immunofluorescence confirmed this shift: CD155 knockdown in H1299 cells promoted YAP cytoplasmic retention, whereas overexpression in A549 cells enhanced nuclear YAP accumulation (Fig. 4E). Collectively, these data show that CD155 promotes YAP stabilization and nuclear translocation by suppressing its Ser127 phosphorylation. To define how YAP/TEAD1 regulates glycolysis, we explored TEAD1-mediated GLUT1 transcription. JASPAR analyzed and predicted the most likely TEAD1 binding site in the GLUT1 promoter. Dual-luciferase reporter assays validated this prediction, showing TEAD1 significantly activates the wild-type GLUT1 promoter (GLUT1 promoter-WT) but not the mutant (GLUT1 promoter-MUT; Fig. 4F). Consistent with the dual-luciferase reporter assays, ChIP assays further confirmed that TEAD1 directly binds to the GLUT1 promoter (sequence: TACTTTCCAT; Fig. 4G). These results identify a novel mechanism: CD155 interacts with YAP to inhibit Ser127 phosphorylation, enhancing YAP stabilization and nuclear translocation. Nuclear YAP binds TEAD1 to transactivate GLUT1, linking CD155 to glycolytic regulation in LUAD. This pathway reveals a key molecular axis for CD155-driven tumor progression, providing potential LUAD therapeutic targets. CD155 regulates glycolysis in LUAD to promote tumor progression through the YAP/TEAD1 signaling pathway To confirm that CD155 promotes LUAD progression via the YAP/TEAD1-glycolysis axis, we knocked down TEAD1 in CD155-overexpressing A549 cells and assessed downstream effects. Glycolytic activity assays showed that TEAD1 knockdown abrogated the CD155-induced elevation of 18F-FDG uptake, lactate production, and ATP levels, while increasing medium pH (Fig. 5A-D), consistent with suppressed glycolysis. Mechanistically, Western blot revealed that TEAD1 silencing reversed the CD155-mediated upregulation of GLUT1, HK2, PKM2 and LDHA (Fig. 5E), validating TEAD1 as a critical mediator of CD155-driven glycolytic protein expression. Functionally, TEAD1 knockdown counteracted the pro-proliferative effect of CD155 overexpression, as shown by reduced cell viability (CCK-8) and colony formation in A549 cells (Fig. 5F-G). Similarly, wound-healing and Transwell assays demonstrated that TEAD1 silencing reversed CD155-induced enhancement of cell migration (Fig. 5H-I). Flow cytometry and Western blot further revealed that TEAD1 knockdown attenuated the anti-apoptotic effect of CD155 overexpression in A549 cells (Fig. 5J). These findings confirm that TEAD1 is indispensable for CD155-mediated glycolytic activation and malignant phenotypes in LUAD. By validating TEAD1 as a downstream effector of CD155, they solidify the functional relevance of the CD155-YAP/TEAD1-glycolysis axis, highlighting its potential as a therapeutic target for disrupting LUAD progression.Fig. 5CD155-promoted glycolysis and tumor progression in LUAD is mediated by the YAP/TEAD1 signaling pathway. A Cell uptake level of 18F-FDG. B Lactate production level. C ATP production level. D pH levels in extracellular culture medium. E The expression levels of glycolysis-associated proteins were detected using Western blot. F–G CCK-8 and colony formation assays were used to detect cell proliferation. H–I Wound-healing and Transwell assays (×200) were used to detect cell migration. J Flow cytometry and Western blot were used to detect cell apoptosis. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. *P < 0.05, **P < 0.01, ***P < 0.001 CD155-promoted glycolysis and tumor progression in LUAD is mediated by the YAP/TEAD1 signaling pathway. A Cell uptake level of 18F-FDG. B Lactate production level. C ATP production level. D pH levels in extracellular culture medium. E The expression levels of glycolysis-associated proteins were detected using Western blot. F–G CCK-8 and colony formation assays were used to detect cell proliferation. H–I Wound-healing and Transwell assays (×200) were used to detect cell migration. J Flow cytometry and Western blot were used to detect cell apoptosis. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. *P < 0.05, **P < 0.01, ***P < 0.001 CD155 promotes the polarization of M0 macrophages to the M2 type TAMs, the most abundant immune cells in the tumor microenvironment, exhibit functional heterogeneity, with M1 TAMs exerting antitumor effects (via proinflammatory cytokines and adaptive immune activation) and M2 TAMs promoting tumor progression through immunosuppression. Thus, targeting M2 TAMs or reprogramming TAMs toward an M1 phenotype represents a promising therapeutic strategy [30–33]. Notably, tumor cell-derived lactate (a byproduct of aerobic glycolysis) maintains an acidic tumor immune microenvironment and drives M2 TAMs polarization [34–36]. Given our findings that CD155 regulates LUAD glycolysis, we hypothesized that CD155 may modulate TAMs polarization via glycolysis. First, IHC staining of LUAD tissues for M2 TAMs’ markers (CD163, stromal-localized; TGF-β, extracellular-localized [37]) revealed that high CD155 expression correlated with elevated CD163 and TGF-β in primary lesions. Correlation analysis confirmed strong positive associations: CD155 with CD163 (r = 0.783, P < 0.001) and TGF-β (r = 0.486, P < 0.001) (Fig. 6A), linking CD155 to M2 TAMs accumulation in vivo.Fig. 6CD155 affects TAMs polarization. A Immunohistochemical analysis of LUAD tissues showed that CD155 was positively correlated with M2-type TAMs markers CD163 and TGF-β (×400). B The co-cultured THP-1 cells were analyzed for mRNA levels of the M1 or M2 macrophages markers using qRT-PCR. C The co-cultured THP-1 cells were analyzed for CD68+ CD163+ TAMs using immunofluorescence (×200). D The co-cultured THP-1 cells were analyzed for TGF-β and IL-10 level of the M2 macrophages cytokine using ELISA. E After application of the glycolytic inhibitor 2-DG, the mRNA levels of M2 macrophage markers were analyzed by qRT-PCR. F After application of the glycolytic inhibitor 2-DG, the level of M2 macrophage cytokine TGF-β and IL-10 were detected by ELISA. G After blocking the Hippo pathway, the mRNA levels of M2 macrophage markers were analyzed by qRT-PCR. H After blocking the Hippo pathway, the level of M2 macrophage cytokine TGF-β and IL-10 were detected by ELISA. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 CD155 affects TAMs polarization. A Immunohistochemical analysis of LUAD tissues showed that CD155 was positively correlated with M2-type TAMs markers CD163 and TGF-β (×400). B The co-cultured THP-1 cells were analyzed for mRNA levels of the M1 or M2 macrophages markers using qRT-PCR. C The co-cultured THP-1 cells were analyzed for CD68+ CD163+ TAMs using immunofluorescence (×200). D The co-cultured THP-1 cells were analyzed for TGF-β and IL-10 level of the M2 macrophages cytokine using ELISA. E After application of the glycolytic inhibitor 2-DG, the mRNA levels of M2 macrophage markers were analyzed by qRT-PCR. F After application of the glycolytic inhibitor 2-DG, the level of M2 macrophage cytokine TGF-β and IL-10 were detected by ELISA. G After blocking the Hippo pathway, the mRNA levels of M2 macrophage markers were analyzed by qRT-PCR. H After blocking the Hippo pathway, the level of M2 macrophage cytokine TGF-β and IL-10 were detected by ELISA. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 To dissect whether LUAD cell-derived CD155 directly modulates TAMs polarization, we induced THP-1 cells to differentiate into M0 macrophages (via PMA) and co-cultured them with CD155-knockdown H1299 cells or CD155-overexpressing A549 cells. qRT-PCR, dual immunofluorescence staining and ELISA analyses revealed that CD155 knockdown in H1299 cells increased mRNA levels of M1 markers (CD86, TNF-α, IL-6) and decreased M2 markers (CD163, TGF-β, IL-10) in co-cultured TAMs. Conversely, CD155 overexpression in A549 cells reduced M1 markers and elevated M2 markers (Fig. 6B). Dual immunofluorescence staining confirmed that CD155 knockdown in H1299 cells reduced the proportion of CD68⁺CD163⁺ cells, while CD155 overexpression in A549 cells increased this population (Fig. 6C). ELISA further showed that CD155 knockdown decreased M2-derived TGF-β and IL-10 secretion, whereas overexpression enhanced it (Fig. 6D), confirming CD155 promotes M2 TAMs polarization. To test whether glycolysis mediates this effect, we treated CD155-overexpressing A549 cells with 2-DG. qRT-PCR and ELISA revealed that 2-DG abrogated the CD155-induced upregulation of M2 markers (CD163, TGF-β, IL-10) and reduced TGF-β and IL-10 secretion (Fig. 6E-F), linking CD155-driven glycolysis to M2 polarization. We next validated the role of the YAP/TEAD1 axis. TEAD1 knockdown in CD155-overexpressing A549 cells reversed the upregulation of M2 markers (CD163, TGF-β, IL-10) and decreased TGF-β and IL-10 secretion (Fig. 6G-H). These findings uncover a novel regulatory cascade: CD155 activates the YAP/TEAD1 axis to enhance LUAD glycolysis, promoting lactate-driven M2 TAMs polarization. This link between tumor cell metabolism and immune microenvironment remodeling identifies CD155 as a dual target for metabolic and immunotherapeutic strategies in LUAD. CD155 regulates glycolysis and promotes tumor progression in vivo To validate CD155’s role in LUAD in vivo, we established subcutaneous tumor models in nude mice using H1299 and A549 cells, respectively. For H1299-derived tumors, mice were injected with CD155-knockdown cells (si-CD155) or controls (si–NC). CD155 knockdown significantly reduced tumor volume and weight compared to controls, confirming in vivo inhibition of LUAD growth (Fig. 7A-C). 18F-FDG micro-PET imaging prior to endpoint revealed decreased 18F-FDG uptake and lower SUVmax in CD155-knockdown tumors, indicating reduced glucose metabolism (Fig. 7D). IHC staining further showed downregulated CD155, along with decreased expression of the proliferation marker Ki-67 and glycolysis-related proteins (GLUT1, HK2, PKM2, LDHA) in knockdown tumors (Fig. 7E). Conversely, using A549 cells with lentivirus-mediated CD155 overexpression (or empty vector controls), we observed that CD155 overexpression significantly increased tumor volume and weight, accelerating LUAD growth in vivo (Fig. 7F-H). 18F-FDG micro-PET confirmed elevated 18F-FDG uptake and higher SUVmax in overexpressing tumors, reflecting enhanced glucose metabolism (Fig. 7I). IHC validated upregulated CD155, Ki-67, and glycolytic proteins in these tumors (Fig. 7J). These in vivo findings align with our in vitro data, conclusively demonstrating that CD155 promotes LUAD progression by enhancing glycolysis. This preclinical validation strengthens CD155’s potential as a therapeutic target, bridging cellular mechanisms to in vivo tumor biology.Fig. 7CD155 affects LUAD progression by regulating glycolysis in vivo. A–C Xenograft tumor sizes in the si-CD155 and control (si–NC) groups of H1299 cells. The volume and weight of tumors in the si-CD155 group were significantly decreased compared to those in the si–NC group. D Representative 18F-FDG micro-PET images of mice in the si-CD155 and si–NC groups of H1299 cells. E Representative hematoxylin-eosin (H&E) images, CD155, Ki-67 and glycolysis-related proteins staining in H1299 xenografts (×400). F–H Xenograft tumor sizes in the lv-CD155 and control (vector) groups of A549 cells. The volume and weight of tumors in the lv-CD155 group were significantly increased compared to those in the vector group. I Representative 18F-FDG micro-PET images of mice in the lv-CD155 and vector groups of A549 cells. J Representative H&E images, CD155, Ki-67 and glycolysis-related proteins staining in A549 xenografts (×400). K Illustration of CD155 oncogenic activity in LUAD. CD155 protein enhances glycolysis by activating the YAP/TEAD1 signaling pathway to promote the progression of LUAD cells and induce polarization of M2 macrophages. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). **P < 0.01, ***P < 0.001 CD155 affects LUAD progression by regulating glycolysis in vivo. A–C Xenograft tumor sizes in the si-CD155 and control (si–NC) groups of H1299 cells. The volume and weight of tumors in the si-CD155 group were significantly decreased compared to those in the si–NC group. D Representative 18F-FDG micro-PET images of mice in the si-CD155 and si–NC groups of H1299 cells. E Representative hematoxylin-eosin (H&E) images, CD155, Ki-67 and glycolysis-related proteins staining in H1299 xenografts (×400). F–H Xenograft tumor sizes in the lv-CD155 and control (vector) groups of A549 cells. The volume and weight of tumors in the lv-CD155 group were significantly increased compared to those in the vector group. I Representative 18F-FDG micro-PET images of mice in the lv-CD155 and vector groups of A549 cells. J Representative H&E images, CD155, Ki-67 and glycolysis-related proteins staining in A549 xenografts (×400). K Illustration of CD155 oncogenic activity in LUAD. CD155 protein enhances glycolysis by activating the YAP/TEAD1 signaling pathway to promote the progression of LUAD cells and induce polarization of M2 macrophages. An independent samples t-test was applied to analyze the differences between the two groups. Data are presented as mean ± SEM (n = 3). **P < 0.01, ***P < 0.001 Discussion Lung adenocarcinoma (LUAD) remains among the most lethal malignancies worldwide, posing a significant clinical challenge despite advances in treatment [38]. Immunotherapy, particularly immune checkpoint blockade targeting the PD-1/PD-L1 axis, has emerged as a groundbreaking therapeutic approach, yet its efficacy in LUAD is limited to approximately 30% of patients [39]. Mechanisms underlying variable response and immune escape are incompletely understood, highlighting the urgent need for novel biomarkers and therapeutic targets [40–42]. Our study fills this critical gap by identifying CD155—a recently recognized immune checkpoint—as a central coordinator of metabolic reprogramming and immune evasion in LUAD. CD155 is known to inhibit CD8⁺ T cell and NK cell cytotoxicity, thereby facilitating immune escape [43, 44]. However, its broader roles in tumor progression, especially its involvement in metabolic regulation and crosstalk with the tumor microenvironment, have remained largely underexplored. Through a comprehensive series of analyses, we demonstrate that CD155 acts as a central regulatory node, linking metabolic reprogramming to immune suppression via a previously unrecognized molecular pathway. This finding expands our understanding of CD155 beyond its established role as a simple immune checkpoint, positioning it as a key driver of LUAD malignancy. Clinically, our analysis of LUAD patient samples revealed that CD155 is significantly elevated in tumor tissues compared to adjacent normal tissues. This overexpression strongly correlates with poor prognosis, advanced clinical stage and lymph node metastasis [45, 46]. Importantly, we integrated 18F-FDG PET/CT, a widely used clinical tool for assessing tumor metabolism, into our study. This analysis demonstrated a direct correlation between CD155 expression levels and in vivo glucose metabolism, as measured by parameters such as SUVmax. This not only establishes a functional association between CD155 and the Warburg effect but also provides a noninvasive tool to assess CD155-mediated metabolic activity in clinical practice. Such a tool could be invaluable for patient stratification, enabling clinicians to identify those most likely to benefit from CD155-targeted therapies. Functionally, our in vitro experiments using LUAD cell lines demonstrate that CD155 plays a causal role in driving glycolysis, knockdown of CD155 reduces glucose uptake, lactate production and ATP generation, while overexpression has the opposite effects. These metabolic changes align with altered malignant phenotypes—CD155 overexpression enhances cell proliferation, migration and resistance to apoptosis, while knockdown suppresses these traits. Critically, treatment with the glycolysis inhibitor 2-DG reverses these effects, confirming that metabolic reprogramming is a key downstream effector of CD155-mediated tumor progression. Mechanistically, we identified a novel CD155-YAP/TEAD1-GLUT1 axis. We confirmed a direct protein-protein interaction between CD155 and YAP. Western blot analysis revealed that CD155 reduces the phosphorylation of YAP at Ser127. This reduction in phosphorylation stabilizes YAP and promotes its translocation into the nucleus [47]. Once in the nucleus, YAP forms a complex with the transcription factor TEAD1 [48–50], which we showed directly binds to the promoter of GLUT1, a critical glucose transporter in LUAD cells. Rescue experiments, where TEAD1 knockdown reverses CD155-driven glycolysis and malignancy, solidify the role of this axis. This study focused on GLUT1 due to its strong correlation with CD155, its high prevalence of expression in LUAD, and the specificity of CD155 in regulating it. Other glucose transporters may play roles in specific subtypes of LUAD, which require targeted exploration in subsequent studies. Beyond cell-autonomous effects, CD155-driven glycolysis shapes the TME to promote immune evasion. Our analysis of LUAD tissues revealed that high CD155 expression correlates with increased infiltration of M2-type TAMs—a subset of immunosuppressive macrophages known to facilitate tumor progression. In vitro co-culture assays further demonstrated that conditioned media from CD155-overexpressing LUAD cells promotes the polarization of THP-1-derived macrophages toward an M2 phenotype. This polarization is mediated by lactate, a byproduct of glycolysis, as treatment with 2-DG abrogates the effect. Notably, the YAP/TEAD1 pathway mediates this metabolic-immune crosstalk, TEAD1 knockdown in CD155-overexpressing cells not only reduces glycolysis but also reverses M2 polarization, confirming a unified regulatory axis. In vivo studies using subcutaneous tumor models in nude mice validated our in vitro findings, CD155 knockdown reduces tumor growth, decreases 18F-FDG uptake, and lowers expression of proliferation markers and glycolytic proteins, overexpression has opposite effects. Conclusions In summary, this study redefines CD155 as a master regulator of LUAD progression, with dual roles: promoting GLUT1-mediated glycolytic reprogramming via the YAP/TEAD1 pathway and driving immune evasion by inducing M2 TAMs polarization through lactate accumulation, establishing it as a novel metabolic-immune checkpoint (Fig. 7K). Targeting CD155 could disrupt tumor metabolism and restore anti-tumor immunity, addressing key resistance mechanisms. Its correlation with 18F-FDG uptake supports PET/CT for noninvasive monitoring, while combinatorial therapies targeting CD155 advance precision oncology to overcome immunotherapy resistance in LUAD. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1